Summary
Danaher Corporation reported a decrease in total sales of 2.5% for the first quarter of 2024 compared to the same period in 2023, with core sales declining by 4.0%. This was primarily driven by a significant drop in the Biotechnology segment, particularly in bioprocessing due to lower customer inventory levels and a tighter credit environment affecting emerging companies. The Diagnostics segment showed resilience with 6.5% total sales growth and 7.5% core sales growth, driven by molecular and clinical diagnostics. The Life Sciences segment experienced a slight 2.0% total sales increase, impacted by acquisitions, but saw a 3.0% decline in core sales due to weaker demand in pharmaceutical and biopharmaceutical customers. Net earnings from continuing operations also declined year-over-year, impacted by the lower core sales and a dilutive effect from recent acquisitions, including a fair value adjustment related to Abcam. The company's liquidity remains strong, with $7.0 billion in cash and cash equivalents as of March 29, 2024, and sufficient operating cash flow to meet its financial obligations, including investments, debt servicing, dividends, and potential acquisitions. Management anticipates the challenging demand in bioprocessing to continue into the second quarter, with gradual improvement expected through the year.
Financial Highlights
50 data points| Revenue | $5.80B |
| Cost of Revenue | $2.31B |
| Gross Profit | $3.49B |
| R&D Expenses | $368.00M |
| SG&A Expenses | $1.81B |
| Operating Income | $1.31B |
| Interest Expense | $65.00M |
| Net Income | $1.09B |
| EPS (Basic) | $1.47 |
| EPS (Diluted) | $1.45 |
| Shares Outstanding (Basic) | 740.60M |
| Shares Outstanding (Diluted) | 748.60M |
Key Highlights
- 1Total sales decreased by 2.5% to $5.8 billion for Q1 2024 compared to Q1 2023, with core sales down 4.0%.
- 2The Biotechnology segment experienced a significant 18.0% total sales decline (17.0% core sales decline), largely due to reduced demand in bioprocessing.
- 3The Diagnostics segment was a bright spot, with total sales up 6.5% and core sales up 7.5%, driven by molecular and clinical diagnostics.
- 4Net earnings from continuing operations were $1.1 billion ($1.45 per diluted share) in Q1 2024, down from $1.2 billion ($1.65 per diluted share) in Q1 2023.
- 5Operating profit margins compressed by 290 basis points due to lower core sales, product mix, reduced leverage, and the dilutive impact of acquisitions.
- 6The company maintains a strong liquidity position with $7.0 billion in cash and cash equivalents as of March 29, 2024.
- 7Management expects the weak demand in bioprocessing to persist into Q2 2024, with gradual improvement anticipated throughout the remainder of the year.